UK markets closed

Epigenomics AG (EPGNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
1.92000.0000 (0.00%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.9200
Open1.9200
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.9200 - 1.9200
52-week range0.4400 - 6.8400
Volume1
Avg. volume189
Market cap22.701M
Beta (5Y monthly)1.10
PE ratio (TTM)N/A
EPS (TTM)-2.0390
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Epigenomics AG plans to issue mandatory convertible bond in the amount of up to EUR 18.15 million

    Epigenomics AG / Key word(s): Bond/FinancingEpigenomics AG plans to issue mandatory convertible bond in the amount of up to EUR 18.15 million11-Jun-2021 / 21:05 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.NOT TO BE PUBLISHED, DISSEMINATED OR PASSED ON TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND

  • EQS Group

    Epigenomics AG successfully completes capital increase

    Epigenomics AG / Key word(s): Capital IncreaseEpigenomics AG successfully completes capital increase18-May-2021 / 08:51 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.NOT FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, JAPAN AND AUSTRALIA.Epigenomics AG successfully completes capital increaseBerlin, 18 May 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY, the "Company") has fully placed the new shares from the capital increase resolved on April 27, 2021. The offer was oversubscribed multiple times. Accordingly, the Company's share capital will be increased from currently EUR 9,852,690.00 by EUR 1,970,537.00 to EUR 11,823,227.00 by 1,970,537 new registered shares of the Company against cash contributions.The gross proceeds from the capital increase amount to approximately EUR 2.2 million.The capital increase needs to be registered in the commercial register, which the Executive Board will apply for shortly. The inclusion of the new shares under the Company's existing listing (ISIN DE000A3H2184) of the remaining shares is currently expected to take place at or around May 26, 2021. Contact:CompanyEpigenomics AGGeneststraße 510829 BerlinTel +49 (0) 30 24345 0Fax +49 (0) 30 24345 555E-mail: ir@epigenomics.com Investor RelationsIR.on AGFrederic Hilke, Fabian KirchmannPhone +49 221 9140 970E-mail: ir@epigenomics.com Important NoticeThis publication does not constitute or form part of, and should not be construed as an offer or an invitation to sell, or issue or the solicitation of any offer to buy or subscribe for, any securities. The shares will be solely offered on the basis of the published subscription offer. This publication does, in particular, not constitute an offer to sell or a solicitation of an offer to purchase any securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the laws of any state within the U.S., and may not be offered or sold in the United States or to or for the account or benefit of U.S. persons, except that the offered shares may be offered or sold to qualified institutional buyers in reliance on certain exemptions from the registration requirements of the Securities Act and applicable state securities laws. This publication and the information contained herein may not be distributed or sent into the United States, or in any other jurisdiction in which offers or sales of the securities described herein would be prohibited by applicable laws, and should not be distributed to United States persons or by way of publications with a general circulation in the United States. No public offering of the shares is being made in the United States. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada, Japan or South Africa or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada, Japan or South Africa. The securities referred to herein have not been and will not be registered under the applicable securities laws of Australia, Canada or Japan. Forward-Looking StatementsThis communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. 18-May-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Epigenomics AG Geneststraße 5 10829 Berlin Germany Phone: +49 30 24345-0 Fax: +49 30 24345-555 E-mail: ir@epigenomics.com Internet: www.epigenomics.com ISIN: DE000A3H2184 WKN: A3H218 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1197550 End of Announcement DGAP News Service

  • EQS Group

    Epigenomics AG Reports Financial Results for the First Quarter of 2021

    DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement/Quarter Results12.05.2021 / 08:00 The issuer is solely responsible for the content of this announcement.Press releaseEpigenomics AG Reports Financial Results for the First Quarter of 2021 Berlin (Germany) and San Diego, CA (U.S.A.), May 12, 2021 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first three months of 2021.Financial key figures Product revenue in the first quarter 2021 decreased from EUR 239 thousand to EUR 106 thousand compared to the prior-year period due to lower product revenues in the United States and Europe. In the current pandemic situation, many patients eligible for screening continue to postpone their screenings. Research and development costs decreased from EUR 1,603 thousand to EUR 737 thousand. Selling, general and administrative costs diminished from EUR 1,992 thousand to EUR 1,601 thousand. EBITDA before share-based payment expenses improved to EUR -985 thousand in the reporting period vs. EUR -2,641 thousand in the same period as the previous year The net loss for the period was EUR -1,201 thousand (Q1 2020: EUR -2,982 thousand); the net loss per share decreased significantly from EUR 0.55 to EUR 0.20 compared to the same period of the previous year. Cash consumption decreased to EUR 1,401 thousand in Q1 2021 (Q1 2020: EUR 3,284 thousand). As of March 31, 2021, the Company had cash and cash equivalents (including marketable securities) of EUR 7,446 thousand (December 31, 2020: EUR 4,527 thousand).Strategic optionsFollowing the negative reimbursement decision by the CMS in January 2021, the management is considering various strategic options. As announced at the end of March, the Company is evaluating, among other things, a potential sale of the Company by way of a share deal (public takeover) or asset deal to one or more investors as part of an M&A transaction. For this purpose, a corresponding sales process has been set up and the Company is in discussions with several potential parties. The Company has mandated a leading international investment bank as advisor in connection with the sale process.Major events after the end of the reporting period The first conversion period for the mandatory convertible bond issued in January 2021, ran from April 1 to April 14, 2021. Bonds with a nominal value of EUR 4,357,606.00 have been converted into 3,961,460 new shares (ISIN DE000A3H2184). Accordingly, the number of issued shares increased from 5,891,230 to 9,852,690 no-par value registered shares of the Company. The Company's share capital increased correspondingly to EUR 9,852,690.00. The outstanding portion of the mandatory convertible bond 2021/2024 therefore has a nominal value of EUR 1,142,394.00. In addition, on April 27, 2021, the Executive Board of Epigenomics AG resolved, with approval of the Supervisory Board, to increase the company's share capital through a rights issue using the Authorized Capital 2020/II. The share capital shall be increased from currently EUR 9,852,690.00 by up to EUR 1,970,537.00 to up to EUR 11,823,227.00 by issuing up to 1,970,537 new registered no par value shares of the Company against cash contributions. The subscription price for the new shares was set at EUR 1.10. The subscription ratio is 5:1. This means for each five existing shares of the Company, a subscription right for one new share will be allocated. Deutsche Balaton Aktiengesellschaft, with 22.59% the largest shareholder of Epigenomics AG, has already announced that it will participate in the capital increase. The capital increase serves the purpose of improving the Company's liquidity position ahead of upcoming important strategic decisions.Outlook 2021Revenue The Company confirms its outlook for fiscal year 2021 and continues to expect revenue within the range of EUR 0.4 million to EUR 1.0 million. If the NCD decision made by CMS is successfully appealed or reversed in 2021, a change in the revenue guidance would be made.EBITDA / Cash consumption For EBITDA before share-based payment expenses, Epigenomics forecasts a range of EUR -7.0 million to EUR -9.0 million. Based on the Company's 2021 business plan, cash consumption is expected to be in line with the EBITDA forecast (before share-based payment expenses).Further InformationThe 2020 Q1 interim statement (unaudited) is available on the Epigenomics' website: https://www.epigenomics.com/news-investors/financial-reports/.Conference call for analysts and investors Epigenomics AG will host a conference call for analysts and investors today at 5.00 pm (CET) / 11.00 am (EDT). The webcast can be accessed on the Company's website: https://www.epigenomics.com/news-investors/financial-reports/.The dial-in numbers for the conference call are:Dial-in number Germany: +49 30 232531508Dial-in number UK: +44 20 3872 0883Dial-in number U.S.A.: +1 516-269-8979Participants are asked to dial in 10 minutes prior to the start of the conference call and to register using the link above.An audio replay of the conference call will be provided on the Epigenomics' website subsequently. About EpigenomicsEpigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer. Based on its proprietary biomarker technology for the detection of methylated DNA, Epigenomics develops and markets blood tests for various cancer indications with high unmet medical need. Epigenomics' lead product is the blood test Epi proColon(R) for the early detection of colorectal cancer. Epi proColon is approved by the U.S. Food and Drug Administration (FDA) and is marketed in the United States and Europe as well as other selected countries. HCCBloodTest, a blood test for the detection of liver cancer, have received the CE Mark for marketing in Europe.For further information please visit www.epigenomics.com. Contact:CompanyEpigenomics AG, Geneststrasse 5, 10829 BerlinTel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, E-Mail: contact@epigenomics.comInvestor RelationsIR.on AG, Frederic Hilke, Tel +49 221 9140 970, E-Mail: ir@epigenomics.com Note on forward-looking statementsThis publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG's actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise. 12.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Epigenomics AG Geneststraße 5 10829 Berlin Germany Phone: +49 30 24345-0 Fax: +49 30 24345-555 E-mail: ir@epigenomics.com Internet: www.epigenomics.com ISIN: DE000A3H2184 WKN: A3H218 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1195463 End of News DGAP News Service